Alto Neuroscience, Inc.
ANRO NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$22.11
KIRA · Stoqly’s AI analyst, in plain words
- Alto Neuroscience, Inc. lost $63.2M in fiscal 2025.
- Free cash flow was −$51.8M in fiscal 2025, — of revenue.
- Alto Neuroscience, Inc. has $160M more cash than debt.
Market cap
$947M
P/E
—
Revenue
—
Net income
−$63.2M
Free cash flow
−$51.8M
Operating margin
—
Alto Neuroscience, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$63.2M
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Alto Neuroscience, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- Alto Neuroscience, Inc.
- CIK
- 0001999480
Alto Neuroscience, Inc. · ANRO
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$36.3M | −$61.4M | −$63.2M |
| Diluted EPS | −$9.73 | −$2.50 | −$2.19 |
| Cash | |||
| Cash from operations | −$33.4M | −$47.4M | −$51.8M |
| Capital expenditure | $0.5M | $2.1M | $0.0M |
| Free cash flow | −$33.9M | −$49.5M | −$51.8M |
| Share count change | — | 559.4% | 17.3% |
| Debt and strength | |||
| Cash and short-term investments | $82.5M | $168M | $176M |
| Debt incl. finance leases | $9.9M | $10.3M | $16.8M |
| Shareholders' equity | −$71.7M | $151M | $151M |
| Current ratio | 15.2x | 16.9x | 15.7x |
| Interest coverage | −27.6x | −49.9x | −26.9x |
| Returns and quality | |||
| Return on equity | — | −154.0% | −41.8% |
| Return on tangible equity | — | −40.6% | −41.8% |
| Piotroski F-score | — | 4 | 2 |
| Altman Z'' | −4.3 | 6.8 | 4.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$3.6M
1 insider
Of sales under plans
100%
$3.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Alto Neuroscience, Inc. · ANRO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $22.11 a share, the company is worth $947M.
Source: SEC EDGAR XBRL filings (CIK 0001999480). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.